Navigation Links
BioMarin to Present at the Jefferies Healthcare Conference
Date:6/10/2009

NOVATO, Calif., June 10 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Senior Vice President and Chief Business Officer of BioMarin, will present a company update at the Jefferies Healthcare Conference in New York City on Wednesday, June 17, 2009 at 8:30 a.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase I clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                       Media
    Eugenia Shen                    Susan Berg
    BioMarin Pharmaceutical Inc.    BioMarin Pharmaceutical Inc.
    (415) 506-6570                  (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin to Present at the Goldman Sachs Healthcare Conference
2. BioMarin to Present at the Deutsche Bank Health Care Conference
3. BioMarin to Present at the Baird Growth Stock Conference
4. BioMarin Announces First Quarter 2009 Financial Results
5. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
6. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
7. BioMarin to Present at the 4th Annual Citi Biotech Day
8. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
9. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
10. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
11. BioMarin to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... ... media network RegMedNet has produced a Spotlight series on ... scholarly reviews and perspectives by leading experts on the unique regulatory challenges of ...
(Date:6/22/2017)... ... June 22, 2017 , ... Charm Sciences, Inc. is pleased to announce that ... to be appropriate as a screening test at dairies and farms for raw commingled ... and the Charm EZ Lite system. These systems are a combination incubator and reader ...
(Date:6/20/2017)... NEWTOWN SQUARE, Pa. , June 20, 2017 /PRNewswire/ ... technology, is pleased to announce the issuance of a ... treating gout or hyperuricemia by the U.S. Patent and ... Biotech Inc., a winner of the Buzz of Bio ... , is akin to developing non-drug approaches to ...
(Date:6/19/2017)... ... 2017 , ... As Vice President, Product Services, Mr. Guinter ... support, and client process and SOP development. , Mr. Guinter brings a wealth ... for service providers and top-tier pharmaceuticals, and as an independent consultant supported a ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
Breaking Biology News(10 mins):